Melqart Asset Management UK Ltd Invests $5.45 Million in Abivax SA Sponsored ADR $ABVX

Melqart Asset Management UK Ltd acquired a new stake in shares of Abivax SA Sponsored ADR (NASDAQ:ABVX) in the third quarter, HoldingsChannel reports. The institutional investor acquired 64,157 shares of the company’s stock, valued at approximately $5,447,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Bank of Hawaii purchased a new position in Abivax during the third quarter valued at approximately $255,000. Quinn Opportunity Partners LLC purchased a new stake in shares of Abivax in the third quarter worth $2,632,000. Marshall Wace LLP bought a new stake in shares of Abivax during the 3rd quarter valued at $16,106,000. Sei Investments Co. bought a new stake in shares of Abivax during the 3rd quarter valued at $5,660,000. Finally, UBS Group AG lifted its stake in shares of Abivax by 2,561.0% during the 3rd quarter. UBS Group AG now owns 4,461,262 shares of the company’s stock valued at $378,761,000 after buying an additional 4,293,606 shares in the last quarter. 47.91% of the stock is owned by hedge funds and other institutional investors.

Abivax Trading Down 1.3%

Shares of Abivax stock opened at $115.50 on Friday. Abivax SA Sponsored ADR has a twelve month low of $4.77 and a twelve month high of $148.83. The company has a quick ratio of 7.86, a current ratio of 7.86 and a debt-to-equity ratio of 0.03. The business has a 50-day moving average price of $118.99 and a 200-day moving average price of $108.69. The firm has a market cap of $9.13 billion, a price-to-earnings ratio of -27.63 and a beta of 1.00.

Abivax (NASDAQ:ABVX) last posted its earnings results on Monday, December 15th. The company reported ($2.46) EPS for the quarter. The company had revenue of ($4.92) million during the quarter. Equities research analysts anticipate that Abivax SA Sponsored ADR will post -2.83 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the company. Wedbush assumed coverage on Abivax in a research note on Tuesday, February 24th. They issued an “outperform” rating and a $110.00 price target for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Abivax in a research report on Wednesday, January 21st. Morgan Stanley lifted their target price on Abivax from $101.00 to $145.00 and gave the company an “overweight” rating in a research note on Friday, January 9th. BTIG Research reissued a “buy” rating and issued a $150.00 price target on shares of Abivax in a report on Wednesday, February 25th. Finally, Citigroup restated a “market outperform” rating on shares of Abivax in a research note on Thursday, January 8th. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Abivax currently has an average rating of “Moderate Buy” and an average target price of $134.75.

Abivax Company Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.